Antibody Reduces Allergic Reactions to Multiple Foods in NIH Trial Drug Can Help Protect Kids With Multiple Food Allergies During Accidental Exposure

https://www.niaid.nih.gov/news-events/antibody-reduces-allergic-reactions-multiple-foods-nih-trial-0?utm_campaign=+59565440&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term= An NIAID study published today in The New England Journal of Medicine found a 16-week course of omalizumab increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as 1 year could eat without an allergic reaction. This Phase 3 clinical trial finding suggests the antibody therapy has the potential to protect children and adolescents if they accidentally eat a food to which they are allergic despite efforts to avoid it. The FDA approved omalizumab (Xolair) for people with food allergy on February 16 based on interim data from the NIAID trial.